Table 1.

Characteristics of the studies using FDG-PET or PET/CT to monitor treatment response in multiple myeloma.

Authors	Year	Country	Study design	Diagnosis	Treatment (no. of patients)	No. of patients	Device	Posttherapy FDG-PET findings		Complete remission
								Persistence of FDG uptake	Normalization of FDG uptake
Jadvar and Conti [9]	2002	USA	Prospective	MM	CRT (2) CT + BMT (1)	3	PET	2	1	1
Mileshkin et al. [15]	2004	Australia	Retrospective	MM	RT	6	PET	3	3	ns
Bredella et al. [16]	2005	USA	Retrospective	MM	CRT + BMT	3	PET	1	2	2
Zamagni et al. [10]	2007	Italy	Prospective	MM	CT + BMT	23	PET/CT	8	15	12
Bartel et al. [11]	2009	USA	Prospective	MM	CT	239	PET	ns	ns	ns
Kim et al. [17]	2009	USA	Retrospective	PLC	RT	11	PET	4 (∗)	7	9 (∗∗)
Dimitrakopoulou-Strauss et al. [12]	2009	Germany	Prospective	MM	CT	19	PET	ns	ns	ns
Sager et al. [18]	2011	Turkey	Retrospective	MM	CT	10	PET/CT	1	9	8
Zamagni et al. [13]	2011	Italy	Prospective	MM	CT (85)	85	PET/CT	54 (improvement in 12)	31	ns
					CT + BMT (192)	192		67 (improvement in 32)	125	ns
Derlin et al. [14]	2012	Germany	Prospective	MM	BMT	99	PET/CT	ns	ns	40

Legend—ns: not specified; CT: chemotherapy; RT: radiation therapy; CRT: chemoradiation therapy; BMT: bone marrow transplantation; MM: multiple myeloma; PLC: solitary plasmacytoma; (^∗): evolution to MM in 2 patients; (^∗∗): late responses in 2 patients.